SAN FRANCISCO (GenomeWeb) – After graduating from Illumina's Accelerator program in 2015 and raising $6 million in a Series A financing round last year, EpiBiome is working on harnessing genomic technology to develop phage-based therapies for bacterial infections.

The South San Francisco, California-based firm has 25 full-time employees and has also received $300,000 in funding from the Gates Foundation and US Department of Defense to use genomics to identify bacterial resistance pathways, as well as factors that make bacteria less pathogenic.